|

FDC fianlimab+cemiplimab Clinical Trials

1 actively recruiting trial across 1 location

No change since May 2026

Also known as: Libtayo, REGN2810, REGN3767

Pipeline

Phase 2: 1

Top Sponsors

  • Regeneron Pharmaceuticals1

Indications

  • Head and Neck Squamous Cell Carcinoma (HNSCC)1
  • Cancer1

Orlando, Florida1 trial

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Orlando Health

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.